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Abstract
Despite being an essential vitamin, folate has been implicated to enhance tumor growth, as evidenced by reports on
overexpression of folate receptor alpha (FRa) in carcinomas. The role of another folate transporter, reduced folate carrier
(RFC), is largely unknown. This study investigated the roles of folate, FRa and RFC in ovarian cancers. We demonstrated FRa
mRNA and protein overexpression and reduced RFC expression in association with FRa gene amplification and RFC
promoter hypermethylation, respectively. FRa overexpression was associated with tumor progression while RFC expression
incurred a favorable clinical outcome. Such reciprocal expression pattern was also observed in ovarian cancer cell lines.
Folate was shown to promote cancer cell proliferation, migration and invasion in vitro, and down-regulate E-cadherin
expression. This effect was blocked after either stable knockdown of FRa or ectopic overexpression of RFC. This hitherto
unreported phenomenon suggests that, RFC can serve as a balancing partner of FRa and confer a protective effect in
patients with high FRa-expressing ovarian carcinomas, as evidenced by their prolonged overall and disease-free survivals. In
conclusion, we report on the paradoxical impact of FRa (putative oncogenic) and RFC (putative tumor suppressive) in
human malignancies. FRa and RFC may potentially be explored as therapeutic target or prognostic marker respectively. We
recommend caution and additional research on folate supplements in cancer patients.
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Introduction
Ovarian carcinomas account for the highest mortality amongst
all gynecological cancers in the world [1,2]. While the incidence of
ovarian carcinomas varies between different ethnic groups, its
incidence in Asian countries is on a rising trend [3,4]. The reasons
for this remain largely unknown or controversial. Several lifestyle
risk factors have been implicated. These include diet, obesity,
fertility and parity statuses. On the other hand, it has became a
general belief that high intake of micronutrients such as folate,
vitamin C, vitamin E may protect against cancers [5]. As such,
better understanding of the effects of nutritional elements on
carcinogenesis is important to improve the strategies for cancer
prevention and management.
Folate is a water-soluble B vitamin found in most vegetables. A
high dietary folate intake has been reported to associate with a
lower risk of developing ovarian cancers, in particular, those who
consume alcohol [6,7,8,9]. It is closely related to its function on
DNA synthesis and its involvement in the related methionine
metabolic pathway essential for DNA methylation. Folate
deficiency would therefore leads to DNA hypomethylation, altered
gene expression and the misincorporation of uracil into DNA,
leading to chromosome damage, all of which, are key factors for
carcinogenesis [10,11]. It would appear that folate is an important
vitamin essential in normal functioning of cells, and to prevent the
initiation of cancer. However, there is increasing evidence to show
that folate may in fact enhance cancer progression in established
carcinomas of colon and rectum, breast and prostate [12,13,14].
Folate uptake involves several transporters, such as folate
receptors, and reduced folate carrier (RFC) [15,16]. Folate
receptor alpha (FRa), a single chain glycosyl-phosphatidylinosi-
tol–anchored membrane protein, enhances folate uptake through
endocytosis. Its overexpression has been reported in ovarian
cancers, implying that it may promote tumor growth
[17,18,19,20]. RFC is an ubiquitously expressed transporter for
natural folates and classical antifolates, and can control folate
uptake in a bi-directional manner [16]. Loss of RFC with
subsequent effects of folate deficiency was found to promote
cancer progression in colorectal cancer [16,21]. It would therefore
be logical to assume that these two folate transporters, FRa and
RFC, exert different effects in cancer progression.
Although overexpression of FRa in ovarian cancers has been
established, the expression status and functional roles of RFC
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remain largely unknown. In this study, we investigated the
expression, genetic and epigenetic profiles of FRa and RFC in
normal ovarian epithelium and ovarian cancer, and correlated
with clinicopathological parameters. Their functional roles and
possible downstream targets on cell proliferation, migration and
invasion in relation to folate in ovarian cancer were also assessed.
We endeavoured to better understand the roles of folate and its
transporters in ovarian carcinogenesis, and explore the possible
effects of folate intake in cancer patients.
Materials and Methods
Clinical Samples and cell lines
One hundred and fifty three formalin-fixed paraffin embedded
samples of ovarian tumors, including 11 inclusion cysts/benign
cystadenomas (22–63 years; mean age, 50 years), 19 borderline
tumors (20,46 years; mean age, 30 years), 83 carcinomas (34 to
83 years; mean 51 years) of different histological subtypes and 44
corresponding metastatic foci (Table 1), were collected from the
Department of Pathology, Queen Mary Hospital, the University of
Hong Kong. All patients underwent surgery and 67 patients with
ovarian cancers were also treated with chemotherapy including
platinum/paclitaxel. The follow-up period ranged from five to 209
months (mean 63 months). Thirty three randomly selected clinical
samples of ovarian tumors and their corresponding normal
counterparts, including fallopian tubes and/or contralateral
ovaries, with available frozen blocks were also retrieved. Informed
consent was obtained by all patients and the use of these clinical
samples was approved by Institutional Review Board of the
University of Hong Kong/Hospital Authority Hong Kong West
Cluster (HKU/HA HKW IRB)(Institutional Review Board
number: UW10-129). Haematoxylin Eosin stained sections of
the frozen blocks of each sample were reviewed by two of us
(A.N.Y.C. and P.P.C.I.) to confirm the diagnosis and to ensure
that more than 80% tumor cells were present in the tumor blocks.
Two immortalized ovarian epithelial cell lines, HOSE 6-3 and
HOSE 17-1, and nine ovarian cancer cell lines, SKOV-3,
OVCAR-3, OVCA 420, OVCA433, OC316, Dov13, ES-2,
TOV21G, SW626 (ATCC; Manassas, VA) were cultured as
previously described [22,23].
Real-time PCR (qPCR)
Total RNA from frozen clinical samples and cancer cell lines
was extracted using Trizol reagent (Invitrogen). Genomic DNA
contamination was removed by treating with DNase I (Invitrogen)
treatment. 2.5 mg total RNA was reverse transcribed by Super-
Script Reverse Transcriptase (Invitrogen, San Diego, CA).
Genomic DNA was extracted using phenol/chloroform (Invitro-
gen). qPCR was performed with ABI Prism 7700 sequence
detection system (Applied Biosystems, Foster City, CA) as
described [22,23,24]. Primer sequences for evaluating mRNA
expression of FRa, RFC and GAPDH (as internal control) were as
follows: FRa sense, 59- AAGTGCGCAGTGGGAGCT -39, and
antisense, 59- CATTGCACAGAACAGTGGGTG -39; RFC
sense, 59- CGAAACCTCGGCTTCGGAGC -39, and antisense,
59- GCACGTAGTAGACCACCAGG -39; GAPDH sense, 59-
TCCATGACAACTTTGGTATCGTG -39, and antisense, 59-
ACAGTCTTCTGGGTGGCAGTG -39. The PCR purity was
confirmed by gel electrophoresis. Primer sequences (sense, 59-
GTATGCATGGCTTCCTGCAGG -39, and antisense, 59-
ACTTGTTAAACCCTGTAGAGAGG -39) for evaluating FRa
gene copy number were designed based on the genomic sequence
of intron 3 and intron 4 of FRa (Ensemble database). TRAT1 was
used as the reference gene [25]. Ovarian cancer samples having $
two-fold increase from their corresponding normal counterparts
were considered as positive for FRa gene amplification.
Immunoblotting
Cells were harvested with lysis buffer (0.125 M Tris, pH 6.8 at
22uC containing 1% NP-40 (v/v), 2 mM EDTA, 2 mM N-
ethylmaleimide, 2 mM PMSF, 1 mM sodium orthovanadate and
0.1 mM sodium okadate], and cleared by centrifugation at 4uC.
Protein concentration was determined by DC (detergent compatible)
protein assay (Bio-Rad Laboratories, Hercules, CA). 20 mg protein
was resolved by SDS-PAGE, transferred to polyvinylidene difluoride
membrane, and hybridized with antibodies specific to FRa (1:1000;
Alexis Biochemical, San Diego, CA; ALX-804-439), RFC (1:1000;
Affinity BioReagents; Golden, CO; PA1-9553), E-cadherin (1:5000;
BD Biosciences; Palo Alto, CA; 610182), and actin (1:1000; Sigma,
St. Louis, MO; A5060) and appropriate secondary antibodies (Santa
Cruz Biotechnology, Santa Cruz, CA). The blots were developed by
Enhanced Chemiluminescence (ECL) Plus detection system (Amer-
sham, Arlington Heights, UK), and visualized with X-ray film (Galen
Medical Group, Chattanooga, TN) [22,23,24].
Immunohistochemistry
Immunohistochemical staining was performed as described in
earlier reports [22,23,24]. For FRa immunohistochemistry,
paraffin sections were treated with goat anti-folate receptor
antibody conjugated with horse radish peroxidase (1:200; Abcam;
Cambridge, MA; ab20572). Since the anti-FRa antibody from
Alexis Biochemical used for immunoblotting failed to have
satisfactory result on immunostaining using paraffin sections,
another antibody from Abcam was used. Although this antibody
may recognize other isoforms of FR, the beta and gamme isoforms
of FR were reported to be predominantly expressed in placenta
and hematopoetic cells but not in other tissues [26,27]. This
antibody can therefore be used to detect FRa immunoreactivity in
ovarian cancers. For RFC immunohistochemistry, chicken anti-
RFC antibody (1:200; Affinity BioReagents) was applied, followed
by biotin-rabbit anti-chicken IgG (H+L). 3-diaminobenzidine-
hydrogen peroxide was used as chromogen. Microwave antigen
recovery using citrate buffer (pH 6.0) was performed. Omission or
substitution of the primary antibody with preimmune IgG serum
was used as a negative control. Intensity in stained epithelial cells
was scored as 0 (negative), 1 (faint), 2 (moderate), and 3 (strong).
The percentage of stained cells was rated as 0 (,5%), 1 (5%–
25%), 2 (26%–50%), 3 (51%–75%) and 4 (.75%). Immunoreac-
tivity was assessed by multiplying the staining intensity by the
percentage of stained cells to give a composite a composite
‘‘Histoscore’’ [22,23]. High and low levels of FRa and RFC were
defined by ‘‘HistoScores’’ cut off at mean.
Demethylation treatment
SKOV-3 and OVCA420 cells were treated with 0, 5 or 10 mM
5-Aza-29-deoxycytidine (5-aza-dc, a DNA methylation inhibitor)
for 72 hours [28]. Control cells were treated with equal volume of
dimethyl sulfoxide (DMSO). Total RNA was extracted from cells.
The transcription activity of RFC was determined by qPCR.
DNA preparation, bisulfite treatment and methylation-
specific PCR (MSP) analysis
Genomic DNA from frozen clinical samples was extracted using
phenol/chloroform. Bisulfite treatment was performed as de-
scribed [28]. Primers specific to the methylated (sense, 59-
TTCGTCGTAGTTTGCGAATG -39, and antisense, 59- CAA-
CACGTACCTAAACGCGA -39) and unmethylated (sense, 59-
FRa and RFC in Ovarian Cancer
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TTTGTTGTAGTTTGTGAATGG -39, and antisense, 59-
ACAACACATACCTAAACACAA -39) RFC promoter A were
reported previously [29]. The annealing temperature was 52uC
and 56uC for methylated and unmethylated promoter A
respectively. MSP products were detected by electrophoresis on
2% agarose gel with ethidium bromide staining. Normal
lymphocyte DNA methylated with Sssl methyltransferase was
used as positive control. Untreated genomic DNA and water
blanks without DNA were used as negative controls.
Stable knockdown of FRa, ectopic overexpression of RFC
and folate treatment in SKOV-3
SKOV-3, an ovarian cancer cell line with relatively high FRa
and low RFC expression, was used. To stable knockdown FRa,
cells were transfected with a set of shRNA constructs against
human FRa, pRS-sh FRa (Origene, Rockville, MD), selected with
puromycin (1.5 mg/ml) [22,23,24]. The pRS vector was used as
controls. To transient overexpress RFC, pcDNA3-RFC plasmid
(kindly provided by Prof L Matherly, Michigan Cancer Founda-
tion) and the empty pcDNA3 vector (control) was transfected into
control SKOV-3 cells using Lipofectamine 2000 (Invitrogen)
[22,23,24]. Cells were cultured in Medium 199 (Invitrogen)/
MCDB 105 (Sigma) medium containing 22.7 nM folic acid and
supplemented with 10% fetal bovine serum (FBS) (JRH Biosci-
ences, Lenexa, KS) [22,23]. shFRa cells and RFC overexpressing
cells (2 days after transfection) were pretreated with folate-free
RPMI 1640 medium (Invitrogen) supplemented with 10%
dialyzed FBS containing 0.6 nM folic acid (Invitrogen) for 2 days,
trysinized, counted, plated for functional assays and then treated
Table 1. Correlation of FRa and RFC immunoreactivities with different diagnostic categories and clinicopathological parameters in
ovarian cancer.
Characteristics Case (n) FRa RFC
Mean ± SD P-value Mean ± SD P-value
Diagnostic categories
Cysts/benign 11 1.7561.30 5.3663.11
Borderline 19 3.9662.47 4.5063.06
Carcinomas 83 7.1063.25 ,0.001* 2.9462.33 ,0.008*
Carcinomas{ 21 8.1463.06 2.4562.40
Metastatic foci{ 44 7.6063.18 0.522{ 3.1161.80 0.128{
Stage (FIGO)
I 28 5.9462.83 2.4561.90
II 12 8.3563.36 3.3861.98
III 25 7.7263.22 3.6062.52
IV 14 7.1463.56 0.092* 2.5762.87 0.188*
I 28 5.9462.83 2.4561.90
II–IV 51 7.7163.31 0.022{ 3.2762.50 0.113{
Histological grade
1 18 5.6861.94 3.6762.46
2 38 7.2163.39 2.6162.16
3 25 8.1863.47 0.042* 2.8062.30 0.262*
Low (1) 18 5.6861.94 3.6762.46
High (2–3) 63 7.6063.43 0.022{ 2.6862.20 0.123{
Histology
Serous 30 8.5363.30 3.2362.85
Clear Cell 20 5.1362.74 2.5062.43
Endometrioid 26 7.6062.83 3.0261.73
Mucinous 7 4.7161.90 0.001* 2.6461.55 0.780*
Non-mucinous 76 7.3263.27 2.9762.39
Mucinous 7 4.7161.90 0.027{ 2.6461.55 0.947{
Chemosensitivity1
Sensitive 56 7.3863.29 2.9962.30
Resistant 15 6.3463.03 0.259{ 2.5062.21 0.564{
Intensity values are expressed as ‘‘Histoscores’’ as specified in Methods.
*Kruskal–Wallis rank test;
{Mann-Whitney test;
{Randomly selected primary carcinomas with matched metastatic foci.
1Chemosensitive-patients remained disease free more than 6 months after completion of first-line chemotherapy.
Those with significant P-values are underlined.
doi:10.1371/journal.pone.0047201.t001
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with different doses of folic acid, a synthetic folate, including 0, 6,
12 and 60 nM. The folic acid concentrations used are based on
the physiological range in plasma, which ranges from ,7 nM in
individuals with a negative folate balance to .50 nM in
individuals with .400 mg/d of folate consumption [30], which is
the estimated folate intake by supplement nonusers in North
America [13]. The folic acid deficiency concentration selected
(12 nM) was based on the observation that such concentration is
Figure 1. Overexpression of FRa in ovarian cancer. (A) qPCR analysis of FRa mRNA in ovarian tumors and the corresponding non-tumor
counterparts. (B) mRNA (upper panel) and protein (lower panel) expression of FRa in two immortalized ovarian epithelial cell lines, HOSE 6-3 and
HOSE-17-1, and nine ovarian cancer cell lines, OVCAR-3, SKOV-3, OVCA 420, OVCA433, OC316, Dov13, ES-2, TOV21G, SW626, as assessed by qPCR and
immunoblotting respectively. (C) Immunoreactivity of FRa in serous (a) and mucinous (e) benign ovarian cystadenomas, serous (b) and mucinous (f)
borderline ovarian tumors and serous (c), mucinous (g), clear cell (d) and endometrioid (h) ovarian carcinomas. Scale bar = 100 mm. (D) Kaplan-Meier
overall (left panel) and disease-free (right panel) survival curves for ovarian cancer patients with high and low levels of FRa (cut off at mean).
doi:10.1371/journal.pone.0047201.g001
FRa and RFC in Ovarian Cancer
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the lowest requirement for cell growth [31]. Protein was extracted
2 days after treatment.
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl
tetrazolium bromide) assay
Cell proliferation was determined by MTT assay (Sigma) as
described [22,24]. Cells were seeded in 96-well plates with 2000
cells/well. At specific time points, 10 ml MTT was added to each
well. Plates were incubated at 37uC for 4 h, followed by addition
of 100 ml DMSO to each well for dye extraction. Cell proliferation
was determined by measuring the absorbance of samples at
570 nm with 630 nm as the reference wavelength.
In vitro migration and invasion assays
In vitro migration and invasion assays were performed as
described [22,23,24]. 1.256105 cells were plated on the upper side
of a Transwell insert and allowed to migrate through an 8-mm pore
size membrane (migration assays) or invade through a Matrigel–
coated membrane (invasion assays). Cells at the upper side of the
membrane were removed and the migrated or invaded cells were
fixed with methanol, stained with 0.5% crystal violet, and counted
under a light microscope in 5 random fields after 24 h or 48 h
respectively.
Statistical Analysis
Statistical analysis was performed using SPSS 15.0 for Windows
(SPSS Inc., Chicago, IL). Mann-Whitney test was used for
comparison between two groups whereas Kruskal–Wallis rank
test was used for comparison among multiple groups. Survival
analysis was performed by Kaplan–Meier analysis and log-rank
test. Cox regression analysis was used for multivariate survival
analysis. P values,0.05 were considered as statistically significant.
Results
Overexpression of FRa was associated with ovarian
tumor progression
By qPCR, significantly higher FRa mRNA was found in cancer
samples when compared with the corresponding non-tumor
counterparts after normalization with GAPDH (P=0.015)
(Figure 1A). By immunohistochemistry, strong FRa immunoreac-
tivity was observed in ovarian cancers in contrast to moderate
staining of FRa in borderline tumors and weak or absence of
staining in benign cystadenomas/inclusion cysts (Figure 1C).
Indeed, significantly higher FRa immunoreactivity was detected in
ovarian cancers and borderline tumors than in benign cystadeno-
mas/inclusion cysts (all P,0.05, Table 1). At cell lines level, six out
of nine ovarian cancer cell lines also showed up-regulation of FRa
mRNA and protein expression with SKOV-3, OVCAR-3 and
SW626 showing strong expression while OVCA 420, Dov13 and
Table 2. Correlation between clinicopathological parameters and mRNA expression of FRa and RFC in ovarian cancers.
FRa RFC
Characteristics mRNA expression mRNA expression
Normal
(no. of cases)
Increased
(no. of cases) P-value*
Normal (no. of
cases)
Decreased
(no. of cases) P-value*
Stage (FIGO)
I 11 5 4 12
II 1 2 1 2
III 2 9 2 9
IV 2 1 0.062 1 2 0.920
Early (I) 11 5 4 12
Late (II–IV) 5 12 0.024 4 13 1.000
Histological grade
1 1 1 0 2
2 11 5 5 11
3 4 11 0.064 3 12 0.545
Low (1–2) 12 6 5 13
High (3) 4 11 0.037 3 12 0.699
Histology
Serous 3 9 2 10
Endometrioid 5 6 4 7
Clear Cell 4 2 1 5
Mucinous 4 0 0.052 1 3 0.695
Non-mucinous 12 17 7 22
Mucinous 4 0 0.044 1 3 1.000
Serous 3 9 2 10
Non-serous 13 8 0.071 6 15 0.443
*Fisher’s exact test. Those with significant P-values are underlined.
doi:10.1371/journal.pone.0047201.t002
FRa and RFC in Ovarian Cancer
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TOV21G showed weak expression when compared with two
normal ovarian epithelium cell lines in which no FRa mRNA and
protein expression was detected (Figure 1B).
In clinical samples, high FRa mRNA expression and immuno-
reactivity were found to be significantly associated with advanced
stages of disease and poor histological grade, factors associated
with tumor aggressiveness (Tables 1 and 2). However, no
significant difference of FRa immunoreactivity was found between
the chemosensitive and chemoresistant cases (Table 1). Kaplan-
Meier-survival analyses also did not reveal association between
high FRa expression and overall or disease-free survival
(Figure 1D).
RFC was down-regulated in ovarian cancers and
correlated with good prognosis of patients
In contrast to FRa, ovarian cancer samples displayed signifi-
cantly lower RFC mRNA when compared with the corresponding
non-tumor counterparts as assessed by qPCR (P=0.001)
(Figure 2A). Immunohistochemical analysis also revealed strong
RFC immunoreactivity in inclusion cysts/benign cystadenomas
and weak expression in ovarian cancers (Figure 2C). Six out of
nine ovarian cancer cell lines also displayed down-regulation of
RFC mRNA and protein expression when compared with two
normal ovarian epithelium cell lines (Figure 2B).
RFC mRNA and immunoreactivity did not correlate with
stages of disease, histological grade and histological subtypes
(Tables 1 and 2). Interestingly, there was a significant association
between low expression of RFC, and shorter overall (P=0.034)
and disease-free (P=0.011) survival (Figure 2D). Moreover,
among ovarian cancers with high FRa expression, the overall
(P=0.007) and disease-free (P=0.008) survival was significantly
longer in those with high RFC expression (Figure 2E).
FRa gene amplification and RFC promoter methylation
contributed to dysregulated gene expression in ovarian
cancers
By qPCR, 11 out of 33 (33.3%) cancer samples displayed FRa
gene (FOLR1, chromosome 11q13.3) amplification when com-
pared with the corresponding non-tumor counterparts. All
amplified cases showed elevated mRNA expression. FRa ampli-
fication was correlated with its mRNA expression (P,0.001,
Fisher’s exact test) (Table 3).
On the other hand, reduced expression of RFC in ovarian
cancers was related to hypermethylation. After treatment of
SKOV-3 and OVCA420 ovarian cancer cells by 5-aza-dc, a DNA
methylation inhibitor, two-fold and 2.5-fold increase of RFC gene
expression was detected respectively (Figure 3A). Furthermore,
promoter hypermethylation of RFC gene (chromosome 21q22.2)
was found in 14 out of 33 (42.4%) ovarian cancer samples by
MSP. Representative examples of MSP were shown in Figure 3B.
In contrast, only 3 out of 33 (9%) of non-tumor samples showed
hypermethylation. Unmethylated alleles were detected in all tumor
and non-tumor samples. Promoter hypermethylation of RFC
significantly inversely correlated with its mRNA expression
(P=0.005, Fisher’s exact test) (Table 3). By MSP, we also detected
RFC promoter hypermethylation in five ovarian cancer cell lines
SKOV-3, OVCA 420, OVCA433, TOV21G and SW626
(Figure 3B), all of them showed down-regulated RFC mRNA
and protein expression (Figure 2B). In contrast, no methylated
alleles were detected (Figure 3B) in the normal ovarian epithelium
cell line HOSE 6-3 and two cancer cell lines OVCAR-3 and
OC316, which displayed RFC mRNA and protein expression
(Figure 2B),
Figure 2. Down-regulation of RFC in ovarian cancers and correlation with prognosis of patients. (A) qPCR analysis of RFC mRNA in
ovarian tumors and the corresponding non-tumor counterparts. (B) mRNA (upper panel) and protein (lower panel) expression of RFC in two
immortalized ovarian epithelial cell lines, HOSE 6-3 and HOSE-17-1, and nine ovarian cancer cell lines, SKOV-3, OVCAR-3, OVCA 420, OVCA433, OC316,
Dov13, ES-2, TOV21G, SW626, as assessed by qPCR and immunoblotting respectively. (C) Immunoreactivity of RFCin inclusion cyst (a) and serous
ovarian carcinomas (b). Scale bar = 100 mm. (D) Kaplan-Meier overall (left panel) and disease-free (right panel) survival curves for ovarian cancer
patients with high and low levels of RFC (cut off at mean). (E) Kaplan-Meier overall (left panel) and disease-free (right panel) survival curves for high
FRa expressed ovarian cancer patients with high and low levels of RFC (cut off at mean).
doi:10.1371/journal.pone.0047201.g002
FRa and RFC in Ovarian Cancer
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Knockdown of FRa altered folate-mediated cell
proliferation in SKOV-3 cells
After confirming the specific knockdown of FRa mRNA and
protein expression in SKOV-3 cells (Figure 4A), we first
determined the effects of FRa on folate-mediated cell proliferation
by MTT assay. On days 2 and 4, no significant change of cell
proliferation was found in control and shFRa SKOV-3 cells after
folate treatment. By day 6, control cells showed proliferation in 12
and 60 nM folate treatment. On Day 8, 6, 12 and 60 nM folate-
treated control cells showed does-dependent proliferation. In
contrast, knockdown of FRa blocked folate-mediated cell prolif-
eration (Figure 4B).
Folate through FRa induced SKOV-3 cell migration and
invasion and down-regulated E-cadherin
Next, we tested the effect of folate and FRa on SKOV-3 cell
migration and invasion. Based on the effects of folate on cell
proliferation, 12 and 60 nM doses were chosen for treating control
and shFRa SKOV-3 cells. Transwell migration and invasion
assays showed that 12 and 60 nM folate significantly induced cell
migration and invasion in control cells whereas knockdown of FRa
blocked folate-mediated cell migration and invasion (Figure 4C).
We then determined the possible downstream target for folate
mediated effect on cell migration and invasion. The expression of
E-cadherin, an important cell–cell adhesion molecule essential for
regulating cell motility, was found to be reduced does-dependently
after folate treatment (Figure 4D). Such down-regulation of E-
Figure 3. Promoter hypermethylation of RFC gene in ovarian cancers. (A) The relative mRNA expression of RFC in SKOV-3 and OVCA 420
after 5-aza-dc treatment with indicated concentrations for 72 hours. Each experiment was performed in triplicate. Bars, means of fold change6SD. *,
P,0.05. (B) Representative ovarian cancers (CA) (upper panel) and ovarian cell lines (lower panel) of MSP on RFC methylation status. M, DNA marker;
P, positive control; N, negative control; M, methylated alleles; U, unmethylated alleles.
doi:10.1371/journal.pone.0047201.g003
Table 3. Correlation of FRa amplification and RFC promoter methylation with their mRNA expression in ovarian cancers.
FRa Gene amplification P-value (Fisher’s exact test)
Non-amplified (no. of cases) Amplified (no. of cases)
mRNA expression Normal (no. of cases) 16 0 ,0.001
Increased (no. of cases) 6 11
RFC Promoter DNA methylation P-value (Fisher’s exact test)
Unmethylated (no. of cases) Methylated (no. of cases)
mRNA expression Normal (no. of cases) 8 0 0.005
Decreased (no. of cases) 11 14
doi:10.1371/journal.pone.0047201.t003
FRa and RFC in Ovarian Cancer
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Figure 4. Folate induced SKOV-3 cell proliferation, migration and invasion and down-regulated E-cadherin through FRa. (A) Stable
knockdown of FRa mRNA and protein in SKOV-3 as detected by qPCR (left panel) and immunoblotting (right panel) respectively. **, P,0.005. (B) Cell
proliferation rate of control and shFRa SKOV-3 cells treated with 6, 12 and 60 nM folate at 2, 4, 6 and 8 days displayed as fold change relative to
FRa and RFC in Ovarian Cancer
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cadherin after folate treatment was also abrogated after knock-
down of FRa.
Ectopic overexpression of RFC in high FRa-expressing
SKOV-3 counteracted folate-mediated cell proliferation,
migration and invasion and restored E-cadherin
expression
We have demonstrated overexpression of FRa and reduced
expression of RFC in ovarian cancers, suggesting that they may
exert opposite roles in the progression of ovarian cancer. More
importantly, in patients with high FRa, the overall and disease-
free survival was significantly longer in those with high RFC
expression, implicating the protective role of RFC in high FRa
cancers. To elucidate such protective role, in vitro functional studies
were performed on FRa-positive SKOV-3 cells with ectopically
expressed RFC after folate treatment. RFC was found to
counteract folate-mediated cell proliferation (Figure 5A), migration
and invasion (Figure 5B). Moreover, down-regulation of E-
control without folate treatment (0 nM). n = 3; *, P,0.05. (C) In vitro migration (left panel) and invasion assays (right panel) in control and shFRa
SKOV-3 cells treated with 0, 12 and 60 nM folate using Transwell membrane without or with Matrigel coating respectively. Upper panels:
representative images of migrating or invading SKOV-3 cells. Lower panels: Cell migration or invasion from SKOV-3 presented as percentage of
control treated with 0 nM folate; n = 3; *, P,0.05; **, P,0.005. (D) Immunoblotting on FRa and E-cadherin using protein lysates prepared from control
and shFRa SKOV-3 (left panel). Relative E-cadherin protein level as analyzed by ImageJ software (US National Institutes of Health); n = 3; *, P,0.05; **,
P,0.005 (right panel).
doi:10.1371/journal.pone.0047201.g004
Figure 5. Ectopic overexpression of RFC in FRa-positive SKOV-3 counteracted folate-mediated cell proliferation, migration and
invasion, and down-regulation of E-cadherin. (A) Cell proliferation rate of SKOV-3 cells with ectopically expressed RFC or control vector
(control) treated with 60 nM folate after 5 days displayed as fold change compared to control without folate treatment (0 nM); n = 3; *, P,0.05. (B) In
vitro migration (left panel) and invasion assays (right panel) in SKOV-3 cells with ectopically expressed RFC or control vector treated with 0 and 60 nM
folate displayed as percentage of control treated with 0 nM folate; n = 3; *, P,0.05; **, P,0.005. (C) Immunoblotting of RFC and E-cadherin using
protein lysates prepared from SKOV-3 cells with ectopically expressed RFC or control vector (left panel). Relative E-cadherin protein level as analyzed
by ImageJ software (US National Institutes of Health); n = 3; **, P,0.005 (right panel).
doi:10.1371/journal.pone.0047201.g005
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cadherin in cells after folate treatment was also abrogated after
overexpressing RFC (Figure 5C).
Discussion
In this study, we demonstrated the progressive increase in FRa
mRNA and protein expression from non-tumor tissues, benign
and borderline tumors to carcinomas. In addition, FRa gene
amplification as a possible mechanism of its overexpression was
also demonstrated for the first time in ovarian cancers. Overex-
pression of FRa in ovarian cancers [19,20] as well as in cancers of
kidney, lung and breast have been previously reported [32]. Our
results also indicate that a high FRa expression correlates with
poor histological grade and advanced stages of disease, suggesting
its roles in ovarian tumor progression.
In contrast to FRa, a lower RFC mRNA and protein expression
in ovarian cancers was found when comparing with normal tissues
or benign tumors. RFC is ubiquitously expressed in normal tissue
and is the major folate transport system for transporting natural
folates, such as 5-methyl or 5-formyl tetrahydrofolate (THF), and
antifolates such as methotrexate (MTX) and pemetrexed [16]. 5-
methyl THF is a cofactor essential for DNA methylation which
normally leads to the suppression of oncogenes [33]. Thus, loss of
RFC has been described to contribute to colonic carcinogenesis
[21]. In this study, we found that reduced expression of RFC was
significantly associated with shorter overall and disease-free
survivals, suggesting that RFC may be considered as a marker
for good prognosis in ovarian cancer patients. Moreover, among
patients with high FRa expressing ovarian cancers, the overall and
disease-free survival was significantly better in those with high
RFC expression than those without, implicating the protective role
of RFC for patients with these tumors.
We also demonstrated that FRa amplification and RFC
promoter methylation correlated with mRNA expression in ovarian
cancers. In earlier reports, RFC promoter methylation has been
found in breast cancer cells [34] and primary lymphomas [35]. Our
findings suggested that up-regulation of FRa (a putative oncogenic
folate transporter) and down-regulation of RFC (a putative tumor
suppressor type folate transporter) were controlled genetically and
epigenetically respectively during ovarian cancer development.
As noted in the introduction above, folate is essential for DNA
synthesis [12,13,14], thereby indirectly exerts its effect on cell
proliferation. Overexpression of the FRa in NIH/3T3 cells has
been reported to induce increased cell growth in vitro and in vivo
[36]. Using folate at various dosages ranging from 12 nM
(considered as dietary deficient in North America) to 60 nM
(considered normal for supplement non-users), we were able to
demonstrate cell proliferation in FRa-positive SKOV-3 cells [13].
Conversely, when the FRa was knockdown by shRNA approach,
this folate-mediated cell proliferation in SKOV-3 cells was lost,
confirming the fact that folate indeed transports through FRa
during the process of ovarian cancer cell proliferation. Similarly,
intracellular expression of anti-FR antibodies in ovarian cancer
cells has been reported to exert growth inhibitory effects as shown
by reduced colony formation in soft agar [37].
Besides its effects on cell proliferation, we also demonstrated for
the first time that folate increased SKOV-3 cell migration and
invasion, possibly through the downregulation of cell-cell adhesion
molecule E-cadherin. This effect was abrogated after the
knockdown of FRa. In ovarian cancer, reduced E-cadherin
expression has been described in the metastases but not in the
corresponding primary ovarian tumors [38]. Patients with such
loss of E-cadherin expression were found to have significantly
shorter survival [39]. Moreover, simultaneous expression of
caveolin-1 and E-cadherin in ovarian cancer cells stabilized
adherens junctions through inhibition of src-related kinases [40]
whereas loss of E-cadherin enhanced ovarian cancer metastasis
through up-regulation of a5-integrin [41]. In our study, we were
able to show E-cadherin down-regulation in folated-treated
SKOV-3 cells, suggesting that the folate-mediated enhancing
effect on ovarian cancer cell migration and invasion probably acts
through FRa via down-regulation of E-cadherin expression.
Interestingly, our study also demonstrates folate-mediated cell
proliferation, migration, invasion and E-cadherin reduction in
FRa-positive SKOV-3. Such effect is abrogated with ectopically
expressed RFC, supporting its tumour suppressive effect in FRa-
expressed cells. This in vitro finding further explains the in vivo
finding that in patients with high FRa expressing ovarian cancers,
the overall and disease-free survival was significantly longer in
those with concomitant high RFC expression.
It has been suggested that vitamin supplements, including folate,
is beneficial to health. Folate is usually taken as folic acid, its
synthetic form, which is fortified in many food products.
Supplementation is often believed to be of value to those who
suffer from long-term illnesses. Nevertheless, the beneficial effect of
folate supplement among cancer patients is controversial
[12,13,14]. Earlier studies have shown that folate plays a dual
role in colorectal, breast and prostate cancers [12,13,14]. Our
results also indicated that folate may potentially enhance the
progression and growth of ovarian cancer cells, in particular, those
with high FRa and low RFC expressions. Although folate may
prevent cancer initiation, once the neoplasia is established, it
appears to enhance cancer progression. Should folate supple-
ments, generally considered by the public as a healthy option,
therefore be taken more cautiously? Additional studies to further
explore the benefits or harmful effects of folate supplement in
cancer patients are necessary.
In conclusion, we demonstrated that folate and FRa contribute
to the progression and growth of ovarian cancer cells through the
regulation of cell proliferation, migration and invasion. In contrast,
RFC can serve as a balancing partner of FRa and seems to exert a
protective role in ovarian cancer patients, conferring longer
survival among patients with cancers that showed a high FRa
expression status. We also demonstrated a mechanistic link
between folate, FRa, RFC and E-cadherin. The potential of
FRa and RFC as alternative molecular therapeutic target or
prognostic marker in ovarian cancers should be further explored,
respectively.
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